News
ABUS
3.140
-0.63%
-0.020
Ultragenyx (RARE) Moves 7.8% Higher: Will This Strength Last?
NASDAQ · 2d ago
MORGAN STANLEY REPORTS 10.3% PASSIVE STAKE IN ARBUTUS BIOPHARMA CORP AS OF MAY 31- SEC FILING
Reuters · 4d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Halozyme (HALO), Arbutus Biopharma (ABUS) and Annexon Biosciences (ANNX)
TipRanks · 5d ago
Weekly Report: what happened at ABUS last week (0603-0607)?
Weekly Report · 5d ago
Arbutus Biopharma Price Target Maintained With a $5.00/Share by HC Wainwright & Co.
Dow Jones · 06/07 15:38
HC Wainwright & Co. Reiterates Buy on Arbutus Biopharma, Maintains $5 Price Target
Benzinga · 06/07 15:29
Promising Phase IIa Results Bolster Buy Rating for Arbutus Biopharma’s cHBV Drug Regimen
TipRanks · 06/07 01:45
Arbutus Biopharma Down Over 8%, on Pace for Largest Percent Decrease Since April 2023 -- Data Talk
Dow Jones · 06/06 18:54
Arbutus Reports Promising Hepatitis B Trial Results
TipRanks · 06/06 16:45
Barinthus Biotherapeutics Presents Updated Data From Two Clinical Trials In Chronic Hepatitis B At EASL Congress 2024
Benzinga · 06/06 15:16
TREATMENT WITH ARBUTUS’ IMDUSIRAN AND VTP-300 ACHIEVES STATISTICAL SIGNIFICANCE IN LOWERING HBSAG LEVELS
Reuters · 06/06 15:15
Buy Rating on Arbutus Biopharma Backed by Promising Hepatitis B Study Results
TipRanks · 06/06 10:29
Arbutus Biopharma Is Maintained at Buy by Chardan Capital
Dow Jones · 06/05 20:30
Arbutus Biopharma Price Target Maintained With a $4.00/Share by Chardan Capital
Dow Jones · 06/05 20:30
Chardan Capital Maintains Buy on Arbutus Biopharma, Maintains $4 Price Target
Benzinga · 06/05 20:20
Arbutus Biopharma’s Promising Phase 2a Trial Results Underpin Buy Rating
TipRanks · 06/05 17:55
Arbutus Biopharma’s Promising HBV Treatment Data
TipRanks · 06/05 10:40
Arbutus's Imdusiran Combined With Short-Term Interferon Successfully Maintains Undetectable HBsAg Levels, Essential For A Functional Cure Of HBV
At the end of treatment, 33.3% of patients had undetectable levels of HBsAg and HBV DNA. 100% of these patients maintained undetectability levels for 24 weeks. Six patients who have stopped all therapy have high levels of anti-HBsAg antibodies.
Benzinga · 06/05 07:50
ARBUTUS’ IMDUSIRAN WITH SHORT COURSE INTERFERON ACHIEVES SUSTAINED UNDETECTABLE HBSAG, A NECESSITY FOR HBV FUNCTIONAL CURE
Reuters · 06/05 06:30
Weekly Report: what happened at ABUS last week (0527-0531)?
Weekly Report · 06/03 09:15
More
Webull provides a variety of real-time ABUS stock news. You can receive the latest news about Arbutus Biopharm through multiple platforms. This information may help you make smarter investment decisions.
About ABUS
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. Its HBV product pipeline includes Imdusiran and AB-101. Imdusiran is its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic product candidate. AB-101 is an oral PD-L1 inhibitor that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for.